Stroke Incidence and Death in Atrial Fibrillation Patients Newly Treated with Direct Oral Anticoagulants

References

• Camm AJ, Accetta G, Ambrosio G, et al. Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. Heart. 2017;103(4):307–314. doi:10.1136/heartjnl-2016-30983227647168
   PubMed Web of Science ®Google Scholar
• Hendriks JM, Gallagher C, Sanders P. Ensuring adherence to therapy with anticoagulation in patients with atrial fibrillation. Heart. 2017;103(17):1308–1309. doi:10.1136/heartjnl-2017-31130528389521
   PubMed Web of Science ®Google Scholar
• Ozaki AF, Choi AS, Le QT, et al. Real-world adherence and persistence to direct oral anticoagulants in patients with atrial fibrillation: a systematic review and meta-analysis. Circulation. 2020;13(3):e005969. doi:10.1161/CIRCOUTCOMES.119.00596932148102
   PubMed Web of Science ®Google Scholar
• Liu C, Du X, Jiang C, et al. Long-term persistence with newly-initiated warfarin or non-VKA oral anticoagulant (NOAC) in patients with non-valvular atrial fibrillation: insights from the prospective China-AF registry. Med Sci Monit. 2019;25:2649–2657. doi:10.12659/MSM.91587530971681
   PubMed Web of Science ®Google Scholar
• Maura G, Billionnet C, Alla F, Gagne JJ, Pariente A. Comparison of treatment persistence with dabigatran or rivaroxaban versus vitamin K antagonist oral anticoagulants in atrial fibrillation patients: a competing risk analysis in the french national health care databases. Pharmacotherapy. 2018;38(1):6–18. doi:10.1002/phar.204629028119
   PubMed Web of Science ®Google Scholar
• Hurtado-Navarro I, García-Sempere A, Rodríguez-Bernal C, Santa-Ana-Tellez Y, Peiró S, Sanfélix-Gimeno G. Estimating adherence based on prescription or dispensation information: impact on thresholds and outcomes. A real-world study with atrial fibrillation patients treated with oral anticoagulants in Spain. Front Pharmacol. 2018;9:1353. doi:10.3389/fphar.2018.0135330559661
   PubMed Web of Science ®Google Scholar
• Yao X, Abraham NS, Alexander GC, et al. Effect of adherence to oral anticoagulants on risk of stroke and major bleeding among patients with atrial fibrillation. J Am Heart Assoc. 2016;5(2). doi:10.1161/JAHA.115.003074.
   Web of Science ®Google Scholar
• Tuppin P, Rudant J, Constantinou P, et al. Value of a national administrative database to guide public decisions: from the systeme national d’information interregimes de l’Assurance Maladie (SNIIRAM) to the systeme national des donnees de sante (SNDS) in France. Revue d’epidemiologie et de sante publique. 2017;65(Suppl 4):S149–S167. doi:10.1016/j.respe.2017.05.004
   PubMed Web of Science ®Google Scholar
• Gabet A, Béjot Y, Olié V. Estimation of the incidence of atrial fibrillation treated by oral anticoagulants in France from 2010 to 2016. Arch Cardiovasc Dis Suppl. 2019;11(1):82. doi:10.1016/j.acvdsp.2018.10.182
   Google Scholar
• Rey G, Jougla E, Fouillet A, Hemon D. Ecological association between a deprivation index and mortality in France over the period 1997–2001: variations with spatial scale, degree of urbanicity, age, gender and cause of death. BMC Public Health. 2009;9:33. doi:10.1186/1471-2458-9-3319161613
   PubMed Web of Science ®Google Scholar
• Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Amer Statist Assoc. 1999;94:496–509.
   Google Scholar
• Sherwood MW, Douketis JD, Patel MR, et al. Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Circulation. 2014;129(18):1850–1859. doi:10.1161/CIRCULATIONAHA.113.00575424552831
   PubMed Web of Science ®Google Scholar
• Paciaroni M, Agnelli G, Caso V, et al. Causes and risk factors of cerebral ischemic events in patients with atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants for stroke prevention. Stroke. 2019:Strokeaha119025350.
   Web of Science ®Google Scholar
• Rohla M, Weiss TW, Pecen L, et al. Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF). BMJ Open. 2019;9(3):e022478. doi:10.1136/bmjopen-2018-022478
   PubMed Web of Science ®Google Scholar
• Pancholy SB, Sharma PS, Pancholy DS, Patel TM, Callans DJ, Marchlinski FE. Meta-analysis of gender differences in residual stroke risk and major bleeding in patients with nonvalvular atrial fibrillation treated with oral anticoagulants. Am J Cardiol. 2014;113(3):485–490. doi:10.1016/j.amjcard.2013.10.03524315113
   PubMed Web of Science ®Google Scholar
• Renoux C, Coulombe J, Suissa S. Revisiting sex differences in outcomes in non-valvular atrial fibrillation: a population-based cohort study. Eur Heart J. 2017;38(19):1473–1479. doi:10.1093/eurheartj/ehw61328073863
   PubMed Web of Science ®Google Scholar
• Piccini JP, Simon DN, Steinberg BA, et al. Differences in clinical and functional outcomes of atrial fibrillation in women and men: two-year results from the ORBIT-AF registry. JAMA Cardiol. 2016;1(3):282–291. doi:10.1001/jamacardio.2016.052927438106
   PubMed Web of Science ®Google Scholar
• Bassand JP, Accetta G, Al Mahmeed W, et al. Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: rationale for comprehensive management of atrial fibrillation. PLoS One. 2018;13(1):e0191592. doi:10.1371/journal.pone.019159229370229
   PubMed Web of Science ®Google Scholar
• Claxton JS, MacLehose RF, Lutsey PL, et al. A new model to predict ischemic stroke in patients with atrial fibrillation using warfarin or direct oral anticoagulants. Heart Rhythm. 2019;16(6):820–826. doi:10.1016/j.hrthm.2018.12.00530550837
   PubMed Web of Science ®Google Scholar
• Pullicino PM, Halperin JL, Thompson JL. Stroke in patients with heart failure and reduced left ventricular ejection fraction. Neurology. 2000;54(2):288–294. doi:10.1212/WNL.54.2.28810668685
   PubMed Web of Science ®Google Scholar
• de Peuter OR, Kok WE, Torp-Pedersen C, Buller HR, Kamphuisen PW. Systolic heart failure: a prothrombotic state. Semin Thromb Hemost. 2009;35(5):497–504. doi:10.1055/s-0029-123414519739040
   PubMed Web of Science ®Google Scholar
• Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology. 2007;69(6):546–554. doi:10.1212/01.wnl.0000267275.68538.8d17679673
   PubMed Web of Science ®Google Scholar
• Lip GYH, Keshishian A, Li X, et al. Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients. Stroke. 2018;49(12):2933–2944. doi:10.1161/STROKEAHA.118.02023230571400
   PubMed Web of Science ®Google Scholar
• Boriani G, Proietti M, Laroche C, et al. Contemporary stroke prevention strategies in 11 096 European patients with atrial fibrillation: a report from the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) Long-Term General Registry. Europace. 2018;20(5):747–757.29016832
   PubMed Web of Science ®Google Scholar
• Sakuma I, Uchiyama S, Atarashi H, et al. Clinical risk factors of stroke and major bleeding in patients with non-valvular atrial fibrillation under rivaroxaban: the EXPAND Study sub-analysis. Heart Vessels. 2019.
   Web of Science ®Google Scholar
• Boriani G, Proietti M, Laroche C, et al. Association between antithrombotic treatment and outcomes at 1-year follow-up in patients with atrial fibrillation: the EORP-AF general long-term registry. Europace. 2019.
   Web of Science ®Google Scholar
• Healey JS, Oldgren J, Ezekowitz M, et al. Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study. Lancet. 2016;388(10050):1161–1169. doi:10.1016/S0140-6736(16)30968-027515684
   PubMed Web of Science ®Google Scholar
• Wicke FS, Schaller MA, Karymova K, Beyer M, Muller BS. Ischemic stroke risk estimation in patients without oral anticoagulation: an observational cohort study based on secondary data from Germany. BMC Cardiovasc Disord. 2019;19(1):94. doi:10.1186/s12872-019-1074-731014253
   PubMed Web of Science ®Google Scholar
• Freedman B, Martinez C, Katholing A, Rietbrock S. Residual risk of stroke and death in anticoagulant-treated patients with atrial fibrillation. JAMA Cardiol. 2016;1(3):366–368. doi:10.1001/jamacardio.2016.039327438123
   PubMed Web of Science ®Google Scholar
• Vrijens B, Heidbuchel H. Non-vitamin K antagonist oral anticoagulants: considerations on once- vs. twice-daily regimens and their potential impact on medication adherence. Europace. 2015;17(4):514–523. doi:10.1093/europace/euu31125694538
   PubMed Web of Science ®Google Scholar